<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335485">
  <stage>Registered</stage>
  <submitdate>14/05/2010</submitdate>
  <approvaldate>3/06/2010</approvaldate>
  <actrnumber>ACTRN12610000453088</actrnumber>
  <trial_identification>
    <studytitle>Pilot study of a new less invasive technique of local anaesthesia for the eye in cataract surgery</studytitle>
    <scientifictitle>Pilot study of Anterior Sub-Tenon Anaesthesia in cataract surgery, to assess quality of anaesthesia and akinesia.</scientifictitle>
    <utrn>U1111-1115-0174</utrn>
    <trialacronym>PASTA</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>new technique of eye anaesthesia for cataract surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A sub-Tenon regional block which is injected anterior to the equator of the globe without dissection, rather than the tradition injections posterior to the equator or after dissection.  There are two comparison groups of either 2% Lignocaine or half/half solution of 0.5% Bupivacaine and 2% lignocaine.  Total volume injected  from 6-10mls.  The injection it self takes 2-3 minutes, but including preparation and observation will take about 20 minutes.</interventions>
    <comparator>The actual injection technique will be the same, requiring between 6-10mls of local anaesthetic, injected over about 2 minutes. However, one group will receive 2% Lignocaine, while the other group receives a half/half solution of 2% Lignocaine and 0.5% Bupivacaine.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To quantify motor movement of each rectus muscle and eye lid using Brahma akinesia score.</outcome>
      <timepoint>10 minutes after Anterior Sub-Tenon Anaesthesia (ASTA) injection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Verbal analogue pain score to assess pain</outcome>
      <timepoint>From the beginning to the end of surgery any pain which is observed by staff or surgeon or reported by the patient will be recorded.  this usually occurs from about 20 minutes after ASTA injection, to about 1 hour from ASTA injection.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Elective patients requiring phaco cataract surgery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Lack of patient consent, previous surgery to the posterior of the eye.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Invitations with full study information are sent to elective patients due to have their surgery one month before.  The Study nurse call patients 2 weeks before surgery to clarify any questions about the study and patients are left to sign the consent at home if they wish to.  On the day of surgery, those who brought in consent forms are given ASTA injection.  One of two types of anaesthetic solution is used by blindly picking a piece of paper from an envelope.</concealment>
    <sequence>The study will involve 60 patients, so 30 pieces of paper will have Lignocain written on it, the other 30 will have Lignocain/Bupivocaine written on it.  Papers are then folded and picked out at random.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>non</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/11/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Sharnie Wu</primarysponsorname>
    <primarysponsoraddress>PO box 431 Lithgow, NSW, 2790</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr Sharnie Wu</fundingname>
      <fundingaddress>PO Box 431, Lithgow, NSW 2790</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr KC Tang</fundingname>
      <fundingaddress>109 Sale St, Orange, NSW, 2800</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr KC Tang</sponsorname>
      <sponsoraddress>109 Sale St, Orange, NSW, 2800</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Ophthalmic regional blocks are some of the most commonly used in Australia.  yet most of them require blind insertions to the posterior of the eye.  This study aims to study a new technique which injects under vision to the anterior of the eye.  In theory this should be a simpler and safer technique.  it's efficacy and safety will be the subject of this study.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service Human Research Ethics Committee - Nepean Campus</ethicname>
      <ethicaddress>Research Office
Ground Floor
Court Building
PO Box 63
PENRITH NSW 2751</ethicaddress>
      <ethicapprovaldate>29/07/2008</ethicapprovaldate>
      <hrec>EC00151</hrec>
      <ethicsubmitdate>12/02/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sharnie Wu</name>
      <address>PO B0x 431 Lithgow, NSW 2790</address>
      <phone>+61 438525488</phone>
      <fax>+61 2 63523638</fax>
      <email>drwu@bigpond.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sharnie Wu</name>
      <address>PO Box 431 Lithgow, NSW 2790</address>
      <phone>+61 438 525488</phone>
      <fax>+61 2 63523638</fax>
      <email>drwu@bigpond.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sharnie Wu</name>
      <address>PO Box 431 Lithgow NSW 2790</address>
      <phone>+61 438525488</phone>
      <fax>+61 2 63523638</fax>
      <email>drwu@bigpond.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>